2014年第56届美国血液学年会(ASH)快递——复发多发性骨髓瘤的治疗策略  

56th Session of the United States in 2014 Hematology Conference( ASH ) express:treatment strategies of relapsed multiple myeloma

作　　者：安娜[1] 黄仲夏[1] 

机构地区：[1]首都医科大学附属北京朝阳医院西院血液科,北京市多发性骨髓瘤医疗研究中心,北京100043

出　　处：《临床药物治疗杂志》2015年第3期14-17,共4页Clinical Medication Journal

摘　　要：目的:探索一个系统性的指导复发多发性骨髓瘤(MM)患者的阶梯治疗策略,并对两种最新的抗骨髓瘤药物——卡非佐米和泊马度胺的临床抉择进行了简单的介绍。方法 :在过去10年的研究发现,新药的应用和自体造血干细胞移植(ASCT)的开展使MM的治疗改善了患者的生存和生活质量,然而这些进步仍无法改变MM复发和不能治愈的事实。结果和结论 :新药的出现使临床医师面临较多的治疗选择,然而仍需要平衡药物疗效、不良反应、费用三者之间的关系,使治疗更加个体化。Objective： This paper attempts to explore a ladder treatment strategy in relapsed multiple myeloma （MM） patients. In addition, clinical decision of the 2 most recent novel drugs, Carfilzomib and Pomalidomide were stressed. Methods： In the past 10 years, studies have found that survival and quality of life improved significantly of MM patients after the new drug and autologous hematopoietic stem cell transplantation （ASCT） therapy, however, these advances are still unable to change the fact of repeated relapse and unable be cured in MM. Results and conclusion： The emergence of new drugs make clinicians face with more treatment options and need to balance the relationship among drug efficacy, adverse reactions and the cost, making treatment more individualized.

关 键 词：多发性骨髓瘤 复发 耐药 

分 类 号：R551.3[医药卫生—血液循环系统疾病]